For their study, researchers assessed the cost-effectiveness and safety of preoperative screening and/or administration of mupirocin to patients over a one-year period. A hypothetical cohort of patients due to undergo total joint arthroplasty were divided into three groups: (1) patients obtaining preoperative screening cultures, followed by administration of mupirocin to patients with cultures positive for MRSA; (2) patients provided empirical preoperative treatment with mupirocin without screening; and (3) patients provided no preoperative treatment or screening.
Their analysis showed patients in the first and second group, who received either both screening and treatment or treatment alone, had better cost-savings than the third group. A sensitivity analysis showed that this conclusion still held when the cost of mupirocin was more than $100 and the cost of surgical site infections ranged from $26,000-250,000.
Related Articles on MRSA:
4 Prognostic Variables Determined to be Risk Factors for MRSA
California Health Department Releases Six Reports on Healthcare-Acquired Infections
MRSA Increases Risk of Death 8-Fold for Children With H1N1
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
